Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.
Stefanutti C, Julius U, Watts GF, Harada-Shiba M, Cossu M, Schettler VJ, De Silvestro G, Soran H, Van Lennep JR, Pisciotta L, Klör HU, Widhalm K, Moriarty PM; MIGHTY MEDIC Multinational Society. Stefanutti C, et al. Among authors: julius u. J Clin Lipidol. 2017 Jul-Aug;11(4):858-871.e3. doi: 10.1016/j.jacl.2017.04.114. Epub 2017 Apr 25. J Clin Lipidol. 2017. PMID: 28572002 Free article. Review.
Lipoprotein apheresis: state of the art and novelties.
Stefanutti C, Julius U. Stefanutti C, et al. Among authors: julius u. Atheroscler Suppl. 2013 Jan;14(1):19-27. doi: 10.1016/j.atherosclerosissup.2012.10.021. Atheroscler Suppl. 2013. PMID: 23357136 Review.
Current view: indications for extracorporeal lipid apheresis treatment.
Schettler V, Neumann CL, Hulpke-Wette M, Hagenah GC, Schulz EG, Wieland E; German Apheresis Working Group. Schettler V, et al. Clin Res Cardiol Suppl. 2012 Jun;7(Suppl 1):15-9. doi: 10.1007/s11789-012-0046-6. Clin Res Cardiol Suppl. 2012. PMID: 22528134 Free PMC article.
Effects of lipoprotein apheresis on PCSK9 levels.
Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM. Julius U, et al. Atheroscler Suppl. 2015 May;18:180-6. doi: 10.1016/j.atherosclerosissup.2015.02.028. Atheroscler Suppl. 2015. PMID: 25936324
First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias.
Stefanutti C, D'Alessandri G, Petta A, Harada-Shiba M, Julius U, Soran H, Moriarty PM, Romeo S, Drogari E, Jaeger BR; MightyMedic (Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast) Working Group. Stefanutti C, et al. Among authors: julius u. Atheroscler Suppl. 2015 May;18:241-50. doi: 10.1016/j.atherosclerosissup.2015.02.036. Atheroscler Suppl. 2015. PMID: 25936332
Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency.
Rodrigues R, Artieda M, Tejedor D, Martínez A, Konstantinova P, Petry H, Meyer C, Corzo D, Sundgreen C, Klor HU, Gouni-Berthold I, Westphal S, Steinhagen-Thiessen E, Julius U, Winkler K, Stroes E, Vogt A, Hardt P, Prophet H, Otte B, Nordestgaard BG, Deeb SS, Brunzell JD. Rodrigues R, et al. Among authors: julius u. J Clin Lipidol. 2016 Mar-Apr;10(2):394-409. doi: 10.1016/j.jacl.2015.12.015. Epub 2015 Dec 24. J Clin Lipidol. 2016. PMID: 27055971
195 results